Pricing Log in Create free account
Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue
+11.9%
EPS
−39.2%
Free cash flow
−52.1%

Quarter to September 2026, against a year earlier

547.08 4.58 +0.84%
Market cap
$137.5B
P/E
34.6×
Fwd P/E
33.2×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Vertex Pharmaceuticals Incorporated (VRTX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 111 added · 79 removed · 88 modified
P2I1A: 8 added · 10 removed · 12 modified 		Inventory outpacing revenue
8-K Nov 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 20, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Aug 27, 2026 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2026 P1I2: 82 added · 43 removed · 77 modified
P2I1A: 19 added · 2 removed · 6 modified
8-K Aug 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 13, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026 P1I2: 229 added · 43 removed · 57 modified
P2I1A: 54 added
8-K May 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 28, 2026 5.02 Departure or appointment of directors or officers
8-K Mar 31, 2026 8.01 Other events
10-K Dec 31, 2025 1: 772 added · 167 removed · 157 modified
1A: no comparison — the Item could not be matched reliably
7: 402 added · 79 removed · 86 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025 P1I2: 9 added · 10 removed · 48 modified
P2I1A: 1 added
8-K Nov 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: 15 added · 31 removed · 52 modified
P2I1A: 3 added · 4 removed · 5 modified
8-K Aug 4, 2025 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025 P1I2: no comparison — the earlier filing's text is no longer kept
P2I1A: 22 added
8-K May 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 4, 2025 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 4, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 5, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 6, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.